Drugs / Ciprofloxacin
Ciprofloxacin
also known as
BAYQ3939 · Cipro · Cipro XR · Cipro Inhale · OTO-201 · CIP · ARD-3150 · BAYO9867 · +19 more
Small molecule targets CYP1A2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 14 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | OTIPRIO | — | 2018-03-02 | fda.gov ↗ |
| Label expansions (7) | US (FDA) | CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER | — | 1997-08-07 – 2015-02-02 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | CIPRO | — | 1994-07-21 – 1997-05-15 | fda.gov ↗ |
| Label expansion | US (FDA) | CILOXAN | — | 1994-10-27 | fda.gov ↗ |
| Approved | US (FDA) | CIPRO | — | 1987-10-22 | fda.gov ↗ |
Trials 164 · started per year
today
US approved 1987
1
1
2
2
3
3
3
6
7
3
2
5
8
7
7
7
9
14
7
7
7
7
6
5
3
7
5
7
7
4
1
1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT00881907 | Mar 2010 → Mar 2014 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT00881491 | Apr 2009 → Jan 2015 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 129 trials · 1 met primary | ||||||
| Phase 1 | NCT06925490 | Jun 2025 → Sep 2026 overdue | pulpitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06478940 | Aug 2024 → Aug 2025 | dental pulp disorder | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT05724628 | Oct → Nov 2023 | appendicitis | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05843708 | Apr → Jul 2023 | — | Servier Bio-Innovation LLC | Completed | No outcome recorded |
| Phase 1 | NCT04090684 | Dec 2019 → Sep 2021 | amyotrophic lateral sclerosis | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04523987 | Feb 2019 → Feb 2027 expected | pancreatic ductal adenocarcinoma | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01976065 | Sep 2014 → Sep 2018 | dental pulp necrosis | Kenneth Hargreaves | Completed | No outcome recorded |
| Phase 1 | NCT02118909 | May → Jun 2014 | — | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 1 | NCT02015507 | Jan → Feb 2014 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT01952444 | Oct 2013 → Apr 2014 | inhalational anthrax | Elusys Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01768663 | Jan → Sep 2013 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT00992329 | Jan → Nov 2013 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT01538667 | Apr → Jul 2012 | respiratory system disorder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01402947 | Jul → Aug 2011 | — | Shire | Completed | Met primary |
| Phase 1 | NCT01386593 | May 2011 → Jan 2012 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01168895 | Jul → Sep 2010 | chronic obstructive pulmonary disease, infectious disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01072942 | Jan → Jun 2010 | chronic obstructive pulmonary disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01059890 | Sep 2009 → Jun 2013 | bacterial infectious disease, brain injury | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00964561 | Aug 2009 → Feb 2010 | anthrax infection | PharmAthene, Inc. | Suspended | No outcome recorded |
| Phase 1 | NCT00961038 | Aug 2009 → Mar 2010 | chronic obstructive pulmonary disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT00832286 | Jul 2009 → Sep 2010 | colonic disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00910351 | Jul 2009 → Oct 2010 | Pseudomonas infection | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01052298 | Apr → Sep 2009 | chronic obstructive pulmonary disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT00785980 | Sep → Oct 2008 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00649155 | Nov 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649662 | Oct 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00138411 | Oct 2005 → Mar 2006 | anthrax infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01372345 | Feb 2005 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01372358 | Jan 2005 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06126731 | Nov 2023 → Jun 2026 overdue | castration-resistant prostate carcinoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02773732 | Dec 2016 → Sep 2021 | acute myeloid leukemia | University of Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01108601 | Apr 2008 → Apr 2011 | hearing loss disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Phase 229 trials · 2 met primary · 2 missed | ||||||
| Phase 2 | NCT07842198 | Mar 2027 → Dec 2029 expected | large B-cell lymphoma, plasma cell myeloma | Zealand University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07028424 | Jul 2025 → Jul 2029 expected | pancreatic ductal adenocarcinoma | GERCOR - Multidisciplinary Oncology Cooperative Group | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06728072 | Mar 2025 → Jul 2035 expected | colorectal cancer | Virginia Commonwealth University | Recruiting | No outcome recorded |
| Phase 2 | NCT06798402 | Feb → Nov 2025 overdue | cutaneous leishmaniasis | Al-Mustafa University College | Recruiting | No outcome recorded |
| Phase 2 | NCT07264842 | Jun 2024 → Apr 2026 overdue | dental pulp necrosis | Dow University of Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06342830 | Jun 2024 → Sep 2025 | periapical periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT05462496 | Mar 2023 → Aug 2027 expected | malignant pancreatic neoplasm | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 2 | NCT05205993 | Jan 2021 → Jan 2024 | chronic endometritis | Genesis Athens Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT04165850 | Nov 2019 → Jan 2021 | amyotrophic lateral sclerosis | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04067011 | Aug 2019 → Mar 2020 | anthrax infection | Emergent BioSolutions | Completed | Mixed |
| Phase 2 | NCT05287425 | Aug 2019 → Aug 2023 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT02682485 | Mar 2017 | intestinal perforation, rectal cancer | University of Chicago | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04447625 | Mar 2017 → Feb 2019 | chronic endometritis | Genesis Athens Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02252978 | Jul 2016 | prostate cancer | Wake Forest University Health Sciences | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02719158 | Feb → Jun 2016 | otitis media | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02620007 | Dec 2015 → Aug 2021 | Crohn disease | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01783106 | Feb 2014 → Apr 2019 | Crohn disease | Royal Liverpool University Hospital | Completed | Missed primary |
| Phase 2 | NCT01753115 | Dec 2012 → Aug 2013 | anthrax infection | Emergent BioSolutions | Completed | Met primary |
| Phase 2 | NCT01359098 | Jul → Oct 2011 | acute otitis externa | Otic Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01279252 | Jul 2011 → Jan 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | King's College Hospital NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT01243437 | Dec 2010 → Jun 2013 | plague | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00889967 | Feb 2010 → Apr 2011 | bronchiectasis | Aradigm Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00930982 | Jun 2009 → Sep 2010 | bronchiectasis | Bayer | Completed | Met primary |
| Phase 2 | NCT00645788 | May 2008 → Jan 2011 | cystic fibrosis | Bayer | Completed | Missed primary |
| Phase 2 | NCT00257699 | May 2006 → Jul 2008 | Crohn's colitis | Mount Sinai Hospital, Canada | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00332163 | Apr 2006 → Jan 2008 | colorectal cancer, exanthem, toxic dermatosis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00438269 | Feb 2003 → Mar 2005 | nosocomial infection, pneumonia | Canadian Critical Care Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT04552431 | Sep 1997 → Aug 2003 | chronic prostatitis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00000641 | ? → Dec 1994 | HIV infectious disease, Mycobacterium avium complex disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07202052 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05678621 | Nov 2022 → Apr 2027 expected | dysgammaglobulinemia, hematopoietic and lymphoid cell neoplasm | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04879030 | Jan → Aug 2020 | chronic obstructive pulmonary disease | Haiphong University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2/3 | NCT04319575 | Dec 2018 → Apr 2020 | suppurative periapical periodontitis | Dr. D. Y. Patil Dental College & Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT07113587 | Apr 2014 → Jul 2017 | infectious peritonitis | Karl Landsteiner Insitute for Nephrology and Haemato-Oncology | Completed | No outcome recorded |
| Phase 330 trials · 3 met primary · 3 missed | ||||||
| Phase 3 | NCT07686055 | Jul 2026 → Feb 2027 expected | urinary tract infection | Megan Bradley | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05079802 | Dec 2021 → Dec 2023 | tooth resorption | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT04636957 | Nov 2020 → Dec 2021 | acute otitis externa | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 3 | NCT04110340 | Feb 2020 → Apr 2024 | bubonic plague, pneumonic plague | University of Oxford | Completed | Met primary |
| Phase 3 | NCT03303677 | Apr → Nov 2018 | chronic rhinosinusitis | University of Florida | Withdrawn | No outcome recorded |
| Phase 3 | NCT04547764 | Jun 2017 → Dec 2018 | dental pulp disorder | King Abdulaziz University | Completed | No outcome recorded |
| Phase 3 | NCT02389036 | May 2017 → Apr 2023 | critical illness polyneuropathy, infectious disease with sepsis | The George Institute | Completed | No outcome recorded |
| Phase 3 | NCT02795949 | Oct 2016 → Jan 2020 | bacterial infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | Met primary |
| Phase 3 | NCT02801370 | Jun → Nov 2016 | acute otitis externa | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02600559 | Oct 2015 → Jul 2016 | otitis media | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02216071 | Jul 2014 → Aug 2015 | acute otitis externa | Exela Pharma Sciences, LLC. | Completed | No outcome recorded |
| Phase 3 | NCT02104245 | May 2014 → Aug 2016 | bronchiectasis | Aradigm Corporation | Completed | Met primary |
| Phase 3 | NCT02106832 | Apr 2014 → Sep 2016 | bronchiectasis | Bayer | Completed | Missed primary |
| Phase 3 | NCT01515007 | Mar 2014 → Aug 2016 | bronchiectasis | Aradigm Corporation | Completed | Missed primary |
| Phase 3 | NCT01949155 | Nov 2013 → May 2014 | otitis media with effusion | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01949142 | Nov 2013 → May 2014 | otitis media with effusion | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01764841 | May 2013 → Mar 2016 | bronchiectasis | Bayer | Completed | Mixed |
| Phase 3 | NCT01561794 | May 2012 → Mar 2015 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00980876 | Apr 2012 → Jan 2015 | acute otitis externa | Farmoquimica S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01733966 | May 2010 → Mar 2012 | diverticulitis of colon | Quanta Medical | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00741052 | Jul 2007 → Oct 2008 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT00137787 | Apr 2005 → Dec 2009 | neutropenia | Center for Supporting Hematology-Oncology Trials | Completed | Missed primary |
| Phase 3 | NCT00670215 | Apr → Oct 2004 | bacterial infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00668122 | Mar 2004 → Jan 2006 | urinary tract infection | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00107081 | Jan 2004 → Dec 2007 | cancer, neutropenia | Swiss Pediatric Oncology Group | Terminated | Mixed Stop: Enrollment |
| Phase 3 | NCT00668044 | Nov 2002 → Nov 2003 | bacterial infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00142272 | May 2001 → Jul 2002 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT00761462 | Oct 1999 → Jan 2008 | infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00003824 | Apr 1999 → Jul 2001 | bladder transitional cell carcinoma | SWOG Cancer Research Network | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00002850 | Mar 1997 → Apr 2011 | bacterial infectious disease, plasma cell myeloma | Gary Morrow | Completed | No outcome recorded |
| Phase 435 trials · 2 met primary · 3 missed | ||||||
| Phase 4 | NCT07704359 | Oct 2026 → Feb 2029 expected | anal fistula | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06709196 | Jan 2025 → Jan 2027 expected | urinary bladder cancer | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT05398679 | Aug 2022 → Dec 2026 expected | infective endocarditis | Fundacion Clinic per a la Recerca Biomédica | Recruiting | No outcome recorded |
| Phase 4 | NCT05600023 | Aug → Oct 2022 | pulpitis | Altamash Institute of Dental Medicine | Completed | No outcome recorded |
| Phase 4 | NCT05199324 | Jun 2022 → May 2026 overdue | gram-negative bacterial infections | Tan Tock Seng Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04948463 | Nov 2021 → Dec 2025 | neutropenia | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03891979 | Jun 2019 → Jun 2020 | malignant pancreatic neoplasm | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT03347461 | Oct 2018 → Jun 2019 | discharging ear, otitis media with effusion | Boston Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03692715 | Sep 2018 → Dec 2024 | nephrolithiasis, ureterolithiasis | Clinical Urology and Epidemiology Working Group | Completed | No outcome recorded |
| Phase 4 | NCT04456712 | Jun → Nov 2018 | — | Beni-Suef University | Completed | No outcome recorded |
| Phase 4 | NCT03228108 | Apr 2018 → Sep 2021 | infectious disease, prostate cancer | Radboud University Medical Center | Completed | Missed primary |
| Phase 4 | NCT03012360 | Feb 2018 → Jul 2024 | — | University Hospital, Lille | Terminated | No outcome recorded |
| Phase 4 | NCT03366207 | Dec 2017 → Jul 2018 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 4 | NCT03051698 | Nov 2016 → Oct 2019 | asthma | T. van der Poll | Terminated | No outcome recorded |
| Phase 4 | NCT02357407 | Jun 2015 → Dec 2016 | infectious disease | Rennes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02505581 | May 2015 → Apr 2017 | — | Hospital Universitari Vall d'Hebron Research Institute | Completed | Met primary |
| Phase 4 | NCT02598362 | Apr 2015 → May 2017 | pyelonephritis | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02375295 | Mar 2015 → Dec 2023 | urolithiasis | University of British Columbia | Unknown | No outcome recorded |
| Phase 4 | NCT03533231 | Jan 2015 → Oct 2017 | acute apical periodontitis, dental abscess, dental pulp necrosis | Tariq Yehia | Completed | No outcome recorded |
| Phase 4 | NCT02173262 | Aug 2014 → Sep 2017 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01723150 | Nov 2013 → Jan 2018 | liver abscess (disease) | National University Hospital, Singapore | Completed | Met primary |
| Phase 4 | NCT01659866 | Aug 2012 → Aug 2015 | infectious disease | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT01542801 | Aug 2011 → Jul 2015 | drug allergy | Korea University | Completed | No outcome recorded |
| Phase 4 | NCT01772615 | May 2011 → Aug 2013 | ulcerative colitis | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00809913 | Dec 2008 → May 2013 | urinary tract infection | Leiden University Medical Center | Completed | Missed primary |
| Phase 4 | NCT00596453 | Jan 2008 → Jun 2011 | prostatitis | Johns Hopkins University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01265173 | Apr 2007 → Jun 2018 | cirrhosis of liver | Korea University | Completed | Missed primary |
| Phase 4 | NCT00126698 | Jan 2005 → Apr 2007 | bacteriuria, urinary tract infection | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00481689 | May 2004 → Sep 2005 | urinary tract infection | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00669994 | Jul → Oct 2003 | urinary tract infection | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00676533 | Jun 2003 → Jan 2004 | urinary tract infection | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00392275 | Nov 2002 → May 2006 | cataract | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT01329588 | Mar 2001 → Apr 2002 | HIV infectious disease, chlamydia trachomatis infectious disease, gonorrhea | CHU de Quebec-Universite Laval | Completed | No outcome recorded |
| Phase 4 | NCT00367913 | Mar 1995 → Sep 2004 | lung disorder | British Thoracic Society | Completed | No outcome recorded |
| Phase 4 | NCT00760032 | — | cirrhosis of liver, infectious disease | Florencia Vargas-Vorackova | Withdrawn | No outcome recorded |
| Phase not applicable31 trials · 2 met primary · 3 missed | ||||||
| — | NCT07239739 | Jun → Nov 2026 expected | periapical periodontitis | Faiz ur rahman | Not yet recruiting | No outcome recorded |
| — | NCT07552870 | Jan → Apr 2026 | cirrhosis of liver | Shahida Islam Medical Complex | Completed | No outcome recorded |
| — | NCT07867951 | Sep 2025 → May 2026 overdue | periapical periodontitis | College of Physicians and Surgeons Pakistan | Recruiting | No outcome recorded |
| — | NCT07836686 | Nov 2024 → Mar 2026 | dental pulp necrosis, pulpitis | Uşak University | Completed | No outcome recorded |
| — | NCT07188935 | Oct 2024 → Jun 2025 | type 2 diabetes mellitus | Al-Mustansiriyah University | Completed | No outcome recorded |
| — | NCT07123792 | Jun 2024 → May 2025 | periodontal disorder | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06158451 | Mar → Aug 2024 | periapical periodontitis | Cairo University | Unknown | No outcome recorded |
| — | NCT05750966 | Jul 2023 → Apr 2026 | cholangitis | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT04678869 | Jun 2022 → Jan 2028 expected | acute lymphoblastic leukemia | University College, London | Active not recruiting | No outcome recorded |
| — | NCT05286931 | Mar 2022 → Dec 2025 overdue | gonorrhea | University of Washington | Recruiting | No outcome recorded |
| — | NCT05024188 | Jan → Jul 2022 | — | Assaf Harofeh MC | Unknown | No outcome recorded |
| — | NCT04593238 | Nov 2020 → Apr 2021 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04763070 | Oct 2020 → Apr 2021 | epilepsy | Mazandaran University of Medical Sciences | Completed | No outcome recorded |
| — | NCT04003181 | Sep 2017 → May 2021 | colon adenocarcinoma, diarrheal disease | University of Aarhus | Completed | No outcome recorded |
| — | NCT05581706 | Sep 2017 → Feb 2020 | — | Ege University | Completed | Mixed |
| — | NCT02961751 | Oct 2016 → Jan 2019 | gonorrhea | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT02189668 | Jul 2014 → Jul 2015 | appendicitis | Peter Minneci | Terminated | Missed primary |
| — | NCT02127749 | Jun 2014 → Dec 2015 | — | Academic Medical Center - University of Amsterdam | Completed | Missed primary |
| — | NCT02033408 | Jan 2014 → Dec 2018 | Crohn's colitis, ulcerative colitis | Shaare Zedek Medical Center | Completed | Met primary |
| — | NCT01929460 | Jan → Nov 2014 | pancreas disorder | Kaiser Permanente | Completed | No outcome recorded |
| — | NCT02196740 | Jun 2013 → Dec 2014 | periapical periodontitis | Lin Jiacheng | Unknown | No outcome recorded |
| — | NCT02340182 | Mar → Sep 2013 | infectious disease with sepsis | W.J. Wiersinga, MD, PhD | Completed | No outcome recorded |
| — | NCT01785641 | Dec 2012 → Dec 2013 | peritonitis | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT01572558 | Feb → Oct 2012 | appendicitis | Karolinska University Hospital | Completed | No outcome recorded |
| — | NCT01344512 | Jun 2011 → Sep 2014 | — | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT01137903 | Apr 2010 → Apr 2011 | osteomyelitis, ulcer of lower limbs | Universidad Complutense de Madrid | Unknown | Missed primary |
| — | NCT00355602 | Jul 2006 → Dec 2008 | ulcerative colitis | University of Dundee | Completed | No outcome recorded |
| — | NCT00190151 | Sep 2004 → Jul 2005 | — | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| — | NCT00153634 | Mar 2004 → Nov 2007 | chronic bronchitis, cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| — | NCT00062231 | Apr 2002 → Oct 2006 | cancer of unknown primary site, infectious disease, leukemia, myelodysplastic syndrome +5 | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | Met primary Stop: Enrollment |
| — | NCT00713999 | Aug 2001 → Apr 2002 | sexually transmitted disease, urinary schistosomiasis | University of Aarhus | Completed | No outcome recorded |
| Comparator or background therapy157 trials | ||||||
| Phase 0 | NCT05100654 Comparator | Apr 2022 → Dec 2027 expected | erectile dysfunction, prosthesis-related infectious disease | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05442736 Comparator | Apr 2022 | infectious disease | British University In Egypt | Completed | No outcome recorded |
| Phase 0 | NCT06149676 Background | Feb 2022 → Dec 2024 | urinary tract infection | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT03326050 Comparator | Feb → Sep 2018 | rhinoscleroma | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT02326103 Comparator | Apr 2015 → Jan 2017 | alcoholic hepatitis, alcoholic liver cirrhosis | University of Helsinki | Completed | No outcome recorded |
| Show all 157 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-04-20 | Iterum Therapeutics, International Limited | Results Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials iterumtx.com ↗
Applying the ARLGs approach retrospectively to our two Phase 3 studies of sulopenem, one each in cUTI and uUTI, respectively, demonstrated that oral sulopenem was comparably more effective than ciprofloxacin in patients with uUTI |
| 2022-03-29 | Respira Therapeutics, Inc. | Results Comparison of Phospholipid-Based Particles for the Delivery of Ciprofloxacin in Bronchiectasis Patients. respiratherapeutics.com ↗ |
| 2021-01-12 | NeuroSense Therapeutics Ltd. | Regulatory Neurosense Granted European Orphan Drug Designation neurosense-tx.com ↗
NeuroSense Therapeutics has gained orphan drug designation for the Ciprofloxacin Celecoxib combination pharmaceutical, PrimeC, by the European Medicine Association (EMA). |
| 2019-06-21 | Iterum Therapeutics, International Limited | Results Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019 iterumtx.com ↗
patients with uUTIs in the community treated with the most commonly prescribed antibiotic for that infection, ciprofloxacin, have a significantly greater rate of treatment failure when the organism is quinolone resistant. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-20 | Iterum Therapeutics, International Limited | Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials iterumtx.com ↗ |
| 2022-03-29 | Respira Therapeutics, Inc. | Comparison of Phospholipid-Based Particles for the Delivery of Ciprofloxacin in Bronchiectasis Patients. respiratherapeutics.com ↗ |
| 2021-01-12 | NeuroSense Therapeutics Ltd. | Neurosense Granted European Orphan Drug Designation neurosense-tx.com ↗ |
| 2019-06-21 | Iterum Therapeutics, International Limited | Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019 iterumtx.com ↗ |
| 2019-05-03 | Glenmark Pharmaceuticals Ltd. India | Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication glenmarkpharma.com ↗ |
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 324 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIPROFLOXACIN | “Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with...” NCT07202091 ↗319“oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral...” NCT00332163 ↗ “Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ...” NCT02389036 ↗ “OBJECTIVE: To evaluate the efficacy and safety of topical ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution relative to ciprofloxacin, 0.3%, otic solution...” PMID 28006041 ↗ Apr 2017 “The purpose of this study is to compare the relative bioavailability of ciprofloxacin 1000 mg ER tablets of Dr.Reddy's with that of CIPRO® XR 1000 mg of Bayer Pharmaceuticals...” NCT01372358 ↗ “This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv)...” NCT02168816 ↗ “In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral...” NCT01111253 ↗ “Once the child starts tolerating oral intake and becomes clinically improved, the treatment will be changed to oral ciprofloxacin (20 mg/kg/day) divided into 2 divided doses)...” NCT04030741 ↗ “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ “Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treating acute otitis externa (AOE) compared with ciprofloxacin,...” PMID 35834251 ↗ Jul 2022 “The purpose of this study is to assess the efficacy of 3 days of azithromycin (AZI) compared to 3 days of ciprofloxacin (CIP) (standard-of-care) for the treatment of children...” NCT03854929 ↗ |
| Known as | ARD-3150 | “In the recent phase-3 ORBIT trials, 48 weeks' treatment with ARD-3150 (inhaled liposomal ciprofloxacin) did not significantly improve symptoms” PMID 32554534 ↗ Oct 2020 |
| Known as | BAYO9867 | “Ciprofloxacin (BAYO9867)” NCT00668044 ↗ |
| Known as | BAYQ3939 | “Ciprofloxacin (BAYQ3939) dry powder for inhalation” NCT02106832 ↗13“Ciprofloxacin (Cipro Inhale, BAYQ3939)” NCT01538667 ↗ “Cipro Inhale (Ciprofloxacin, BAYQ3939)” NCT01168895 ↗ “Ciprofloxacin (Cipro InhaIe, BAYQ3939)” NCT01072942 ↗ “Ciprofloxacin (Cipro Inhale, BAYQ3939)” NCT00645788 ↗ “Ciprofloxacin (Cipro inhale, BAYQ3939)” NCT01052298 ↗ “Ciprofloxacin (PulmoSphere, BAYQ3939)” NCT00961038 ↗ “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00668122 ↗ “Drug: Ciprofloxacin DPI (BAYQ3939)” NCT01764841 ↗ “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00676533 ↗ “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00481689 ↗ |
| Known as | Ciloxan | “Groups 1, 2 and 3 received topical ofloxacin 0.3% (Ocuflox), ciprofloxacin 0.3% (Ciloxan) and levofloxacin (Quixin) respectively;” PMID 18211932 ↗ Jan 2008 |
| Known as | CIP | “The purpose of this study is to assess the efficacy of 3 days of azithromycin (AZI) compared to 3 days of ciprofloxacin (CIP) (standard-of-care) for the treatment of children...” NCT03854929 ↗1“Ciprofloxacin hydrochloride (CIP) in chitosan coated PLGA nanoparticles (CIP-CS-PLGA-NPs) and free CIP were embedded in Pluronic® 407/188 to form thermosensitive gels(F1) and...” NCT05442736 ↗ |
| Known as | Cipesta | “one Cipesta™ (ciprofloxacin) 500 mg tablet” NCT07867951 ↗ |
| Known as | Cipro | “Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in...” NCT05581706 ↗8“Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic” NCT02189668 ↗ “Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)” NCT01731236 ↗ “All subjects will be treated with Cipro, an antibiotic, for 5 days.” NCT00654108 ↗ “ciprofloxacin (Cipro, 750 mg tablets, Biofarma, Turkiye)” NCT06818578 ↗ “Group 1: Topical 0.3% Ciprofloxacin [Cipro]” NCT04204954 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT00930982 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT00910351 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT01561794 ↗ |
| Known as | Cipro InhaIe | “Ciprofloxacin (Cipro InhaIe, BAYQ3939)” NCT01072942 ↗ |
| Known as | Cipro Inhale | “Cipro Inhale (Ciprofloxacin, BAYQ3939)” NCT01168895 ↗3“Ciprofloxacin (Cipro Inhale, BAYQ3939)” NCT00645788 ↗ “Ciprofloxacin (Cipro inhale, BAYQ3939)” NCT01052298 ↗ “Ciprofloxacin (Cipro Inhale, BAYQ3939)” NCT01538667 ↗ |
| Known as | Cipro IR | “Cipro IR (Ciprofloxacin, BAYQ3939)” NCT00668122 ↗ |
| Known as | CIPRO IV | “Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]” NCT05162625 ↗ |
| Known as | Cipro XR | “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00676533 ↗4“Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00481689 ↗ “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00668122 ↗ “Cipro® XR Tablets (500 mg” NCT00649155 ↗ “Cipro® XR Tablets 1000 mg” NCT00649662 ↗ |
| Known as | Ciprocin | “Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt)” NCT03533231 ↗ |
| Known as | Ciprofloxacin (Cetraxal) | “Ciprofloxacin (Cetraxal)” NCT02168816 ↗ |
| Known as | ciprofloxacin (Cifran) | “ciprofloxacin (Cifran)” NCT01761214 ↗ |
| Known as | Ciprofloxacin hydrochloride | “Ciprofloxacin hydrochloride (CIP) in chitosan coated PLGA nanoparticles (CIP-CS-PLGA-NPs) and free CIP were embedded in Pluronic® 407/188 to form thermosensitive gels(F1) and...” NCT05442736 ↗ |
| Known as | Ciprofloxacin Inhale | “Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days” NCT01072942 ↗ |
| Known as | Ciprofloxacin Ophthalmic solution | “Ciprofloxacin Ophthalmic solution” NCT03519516 ↗ |
| Known as | Ciprofloxacin tablets USP 39 | “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ |
| Known as | Ciproxin | “Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).” NCT06798402 ↗ |
| Known as | Ciproxin - ciprofloxacin | “Ciproxin ® - ciprofloxacin” NCT01400750 ↗ |
| Known as | CPFX | “Ciprofloxacin (CPFX) is a potential alternative in patients with febrile neutropenia (FN) because of its activity against Gram-negative organisms.” PMID 23317527 ↗ Jan 2013 |
| Known as | FoamOtic Cipro | “Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro (0.3% Ciprofloxacin Otic Foam) Compared to Twice-Daily Dosing of Ciloxan” NCT01157819 ↗ |
| Known as | Otiprio | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03347461 ↗ |
| Known as | OTO-201 | “a single-dose intratympanic, intraoperative, thermosensitive, otic suspension of ciprofloxacin (OTO-201) in children requiring TTP.” PMID 26985629 ↗ May 20162“6 mg OTO-201 (sustained-release suspension of ciprofloxacin)” NCT02719158 ↗ “OTO-201 (ciprofloxacin)” NCT02600559 ↗ |
| Known as | Pulmaquin | “inhaled Pulmaquin (ciprofloxacin dispersion for inhalation)” NCT01515007 ↗ |
| Known as | PulmoSphere | “Ciprofloxacin (PulmoSphere, BAYQ3939)” NCT00961038 ↗ |
| Action | Inhibit | “Ciprofloxacin suppresses the gram negative aerobic bacterial flora including E.coli strains” NCT00609973 ↗ |
| Modality | Small molecule | “Although optimization of the fluoroquinolone dosage increases the efficacy of this class of drugs against bacterial infections” PMID 19563257 ↗ Aug 2009 |
| Route | Oral | “ciprofloxacin, clofazimine, ethambutol, and rifampin (all taken orally)” NCT00000641 ↗ |
| Target | CYP1A2 | “Ciprofloxacin is moderate inhibitor of cytochrome P450 1A2 (CYP1A2)” NCT00785980 ↗ |